# Feline Chronic Kidney Disease: Management and Monitoring Protocol ## Key Takeaways - Feline chronic kidney disease (CKD) management prioritizes slowing progression and maintaining quality of life, with therapy tailored to the individual cat's IRIS stage, comorbidities, and owner-reported wellbeing. - Key modifiable factors driving CKD progression include hyperphosphatemia, systemic hypertension, and anemia, necessitating targeted interventions such as dietary phosphorus restriction, blood pressure control with amlodipine, and management of anemia. - Regular monitoring of systolic blood pressure (target < 140 mmHg on amlodipine), plasma phosphate (stage-specific IRIS targets), urine protein:creatinine ratio (UPC > 0.4 indicates proteinuria), body weight, hydration status, and renal biomarkers (creatinine, SDMA) is critical for detecting changes and adjusting therapy. - Fluid therapy, primarily subcutaneous administration of isotonic balanced electrolyte solutions, is essential for maintaining hydration and adequate perfusion in stable outpatients, with volume and frequency titrated to individual needs and tolerance. - Nutritional management, focusing on palatable, phosphorus-restricted renal diets, is the intervention with the strongest evidence for slowing CKD progression, with intestinal phosphate binders used when diet alone is insufficient. - Hypertension management involves routine blood pressure measurement in all CKD cats, with amlodipine besylate as the first-line agent, and monitoring for target organ damage (ocular, cardiac, neurological) is crucial. --- This article provides a structured framework for the long-term management of feline chronic kidney disease (CKD) in first-opinion and referral practice. It is written for veterinarians who have already established the diagnosis and now require a practical, staged approach to therapy, monitoring, and client communication. The protocol integrates the International Renal Interest Society (IRIS) staging system, nutritional intervention, blood pressure control, and fluid therapy, with emphasis on adjusting treatment to the individual patient's changing needs. CKD in cats is typically progressive, although the rate of progression varies widely between individuals. The [ISFM consensus guidelines on feline CKD](https://pubmed.ncbi.nlm.nih.gov/26936494/) emphasize that therapy must be tailored through careful and repeat evaluation instead of applied as a fixed protocol. Management therefore rests on two parallel objectives: slowing disease progression where possible and maintaining quality of life. These goals sometimes conflict, and the clinician must be prepared to prioritize interventions based on the cat's current stage, comorbid conditions, and owner-reported wellbeing. The histopathological substrate of feline CKD is predominantly chronic tubulointerstitial nephritis, with interstitial fibrosis, tubular atrophy, and secondary glomerulosclerosis. Primary glomerulopathies with marked proteinuria are uncommon in cats compared with dogs. [Histomorphometric studies of feline CKD](https://pubmed.ncbi.nlm.nih.gov/22773469/) have shown that interstitial fibrosis correlates most strongly with the severity of azotemia, hyperphosphatemia, and anemia, while proteinuria is associated with both fibrosis and glomerular hypertrophy. These findings explain why phosphorus restriction and proteinuria assessment occupy central positions in the management plan. ## At a Glance | Parameter | Target or Action | Monitoring Frequency | |---|---|---| | IRIS stage | Assign at diagnosis and restage after stabilization | At each recheck | | Systolic blood pressure | Target below 140 mmHg on amlodipine therapy | Every 2 to 4 weeks until controlled, then every 3 months | | Plasma phosphate | Stage-specific targets per IRIS guidelines | Every 2 to 4 weeks after diet or binder change, then every 3 months | | Urine protein:creatinine ratio | Repeat if initially elevated, treat if persistently above 0.4 | At diagnosis and at each stage change | | Body weight and muscle condition score | Stable or improving | Every visit | | Hydration status | Clinical assessment plus hematocrit and total protein | Every visit | | SDMA or creatinine trend | Stable or slowly rising | Every 3 to 6 months in stable cats | | Serum potassium | Maintain low-normal to normal range | With each biochemistry panel | ## Pathophysiology Relevant to Management The progression of feline CKD is driven by several interacting mechanisms. Hyperphosphatemia develops as glomerular filtration rate falls, and dietary phosphorus intake directly influences progression. The [pathogenetic review of CKD in aged cats](https://pubmed.ncbi.nlm.nih.gov/26869151/) identifies dietary phosphorus intake, magnitude of proteinuria, and anemia as factors related to progression of established disease. These three factors are all modifiable, which makes them the primary targets of long-term therapy. Systemic hypertension occurs in roughly one in five cats with CKD and is a major determinant of morbidity through target organ damage affecting the eye, heart, brain, and kidneys. The [ISFM consensus guidelines on feline hypertension](https://pubmed.ncbi.nlm.nih.gov/28245741/) note that routine blood pressure monitoring is performed infrequently in practice, leading to underdiagnosis. Because hypertension is often silent until target organ damage has occurred, regular measurement is a mandatory component of the CKD monitoring protocol instead of an optional extra. Anemia in feline CKD results from reduced renal erythropoietin production, and its severity correlates with the degree of interstitial fibrosis. Chronic kidney disease also causes qualitative and quantitative disturbances in potassium balance, with hypokalemia being more common than hyperkalemia in non-oliguric cats. Both anemia and potassium derangements contribute to muscle weakness, poor appetite, and reduced quality of life, and both are amenable to targeted therapy. ## The IRIS Staging System The IRIS system provides the common language for CKD management. Staging is based on fasting plasma creatinine concentration, with substaging according to proteinuria and systolic blood pressure. The system is published and updated by the International Renal Interest Society, and the [ACVIM consensus statement collection](https://www.acvim.org/Animal-Owners/Animal-Education/Consensus-Statements) serves as a companion resource for evidence-based decision making in internal medicine. Staging should be performed on a stable patient. A cat that presents dehydrated or with prerenal azotemia may be assigned a falsely high stage, and rechecking after fluid correction is essential before committing to a long-term plan. Substaging for proteinuria uses the urine protein:creatinine ratio, with values above 0.4 considered proteinuric in cats. Blood pressure substaging follows the categories defined in the hypertension guidelines, with systolic pressure above 160 mmHg generally warranting intervention in the context of CKD. The stage determines the intensity of monitoring and the threshold for initiating specific therapies. Early-stage cats may require little more than dietary modification and periodic rechecks, while late-stage cats need integrated management of phosphate, blood pressure, potassium, anemia, and hydration. The [ISFM CKD guidelines](https://pubmed.ncbi.nlm.nih.gov/26936494/) stress that therapy must be adjusted according to individual needs, and the stage provides the initial framework for those adjustments. ## Goals of Long-Term Management The management plan has four interlocking goals: slow progression, control blood pressure, maintain hydration and nutrition, and preserve quality of life. These goals are pursued simultaneously, but their relative priority shifts as the disease advances. In early CKD, slowing progression through dietary phosphorus restriction and blood pressure control dominates. In late CKD, maintaining appetite, hydration, and owner-perceived quality of life becomes increasingly important, sometimes at the expense of laboratory targets. Progression is not inevitable in every cat. Some cats remain stable for years, while others decline rapidly. The monitoring protocol is designed to detect change early, allowing therapy to be intensified before clinical decompensation occurs. Regular rechecks also provide the opportunity to identify new complications such as hypertension, which may develop at any stage of the disease. ## Fluid Therapy in Stable CKD Maintenance of hydration is central to managing feline CKD, but the approach differs sharply between the hospitalized and the home environment. In the stable outpatient, the goal is to offset obligatory renal water losses and maintain adequate perfusion without precipitating volume overload. The ISFM consensus guidelines on feline CKD emphasize that fluid requirements vary between individuals and that therapy must be adjusted according to repeated evaluation of the patient. For cats that are dehydrated or azotaemic at recheck examination, subcutaneous fluid administration is the most practical option for owner-administered support. Isotonic balanced electrolyte solutions are preferred over 0.9% saline because they better match feline plasma electrolyte composition and avoid exacerbating metabolic acidosis. The volume and frequency of subcutaneous fluids should be titrated to the individual cat. A common starting point is 100 to 150 mL given every 24 to 48 hours, but the correct regimen depends on the cat's tolerance, hydration status, and owner capability. Current formulary references should be consulted for specific product recommendations and administration guidance. Decision points that should trigger adjustment of fluid therapy include: - Persistent azotaemia despite adequate intake - Clinical dehydration detected on skin turgor or mucous membrane assessment - Deteriorating appetite or activity level - Development of hypertension, which may indicate volume expansion - Electrolyte derangements, particularly hypokalemia Cats with compensated CKD often maintain hydration with free access to water and a moisture-rich diet. Additional subcutaneous fluids are indicated when polydipsia cannot compensate for urinary losses, when the cat is anorexic or vomiting, or when azotaemia progresses. Conversely, cats with cardiac disease or those developing hypertension may not tolerate aggressive fluid administration, and the clinician must balance renal perfusion needs against cardiovascular risk. ## Nutritional Management Dietary modification is the intervention with the strongest evidence for slowing CKD progression in cats. The ISFM guidelines identify dietary phosphorus restriction as a key component of management, and the panel graded the evidence for renal diets as supportive of improved outcomes. The histopathological correlation between interstitial fibrosis and hyperphosphatemia in aged feline kidneys further supports aggressive phosphorus control. Renal diets are formulated to restrict protein, phosphorus, and sodium while providing increased potassium, B vitamins, and omega-3 fatty acids. The protein restriction is moderate, not severe, and is designed to reduce uremic toxin production while avoiding malnutrition. The ISFM guidelines recommend that dietary phosphorus restriction be introduced early in the disease course, ideally from IRIS stage 2 onward, with the addition of intestinal phosphate binders when diet alone fails to control serum phosphorus. Selection of a renal diet should consider: - Palatability, as poor intake is the most common reason for dietary failure - The cat's body condition and muscle mass - Concurrent disease, such as hyperthyroidism or diabetes mellitus - The owner's ability to provide a prescription diet exclusively Transition to a renal diet should be gradual, over 7 to 14 days, mixing increasing proportions of the new food with the previous diet. Appetite stimulants such as mirtazapine may be needed during the transition period in anorexic cats. If the cat refuses all renal diets, the clinician should prioritize adequate caloric intake over dietary perfection, as malnutrition accelerates CKD progression. Serum phosphorus should be measured at each recheck. The ISFM guidelines recommend maintaining serum phosphorus within the reference interval for the laboratory, with more aggressive targets in advanced disease. When dietary restriction is insufficient, intestinal phosphate binders should be added. These agents are given with food, and dosing should be titrated against serum phosphorus measured two to four weeks after any change. ## Blood Pressure Control Systemic hypertension is a common comorbidity in feline CKD, and its management is a priority because of the risk of target organ damage to the eye, brain, heart, and kidneys. The ISFM consensus guidelines on feline hypertension recommend routine blood pressure measurement in all cats with CKD, with the frequency of monitoring determined by the stage of disease and the presence of hypertension. Blood pressure should be measured using a consistent, validated technique. Doppler sphygmomanometry is the most widely used method in practice, while oscillometric devices are acceptable if validated for cats. The ISFM guidelines recommend that blood pressure be measured in a quiet room, after the cat has acclimated for 5 to 10 minutes, with the cuff placed on a forelimb or the tail. Multiple readings should be taken, and the average of the lowest consistent values should be used for clinical decisions. | Blood Pressure Category | Systolic Pressure (mmHg) | Clinical Action | |-------------------------|--------------------------|-----------------| | Normotensive | < 140 | Recheck in 3 to 6 months | | Pre-hypertensive | 140 to 159 | Recheck in 1 to 2 months, monitor for target organ damage | | Hypertensive | 160 to 179 | Initiate therapy if target organ damage present, recheck in 2 to 4 weeks | | Severely hypertensive | ≥ 180 | Initiate therapy, recheck in 1 to 2 weeks | Amlodipine besylate is the first-line antihypertensive agent in cats, and the ISFM guidelines identify it as the treatment of choice. The dose must be individualised, as the required dose varies between cats. Therapy should be initiated at the lowest available dose and titrated upward based on blood pressure response measured two weeks after each dose change. Most cats respond to amlodipine monotherapy, but some require adjunctive agents such as an ACE inhibitor, particularly when proteinuria is present. The target blood pressure for treated cats is a systolic pressure below 160 mmHg, with an ideal target below 150 mmHg. Once blood pressure is controlled, rechecks should occur every 3 to 6 months, with more frequent monitoring in cats with concurrent disease or those requiring multiple antihypertensive agents. ## Monitoring Schedule and Treatment Adjustment A structured monitoring schedule is essential for detecting progression and adjusting therapy before clinical decompensation occurs. The ISFM guidelines recommend that the frequency of rechecks be determined by IRIS stage, with more advanced disease requiring more frequent evaluation. | Parameter | Frequency | What It Detects | Action Threshold | |-----------|-----------|-----------------|------------------| | Body weight and body condition score | Every 1 to 3 months | Muscle wasting, malnutrition | Weight loss > 5% prompts nutritional intervention | | Serum creatinine and SDMA | Every 3 to 6 months (stable), every 1 to 2 months (advanced) | Progression of azotaemia | IRIS stage change prompts therapy adjustment | | Serum phosphorus | Every 3 to 6 months | Dietary compliance, need for binders | Above reference interval prompts binder initiation or dose increase | | Serum potassium | Every 3 to 6 months | Hypokalemia, which worsens renal function | Below reference interval prompts supplementation | | Blood pressure | Every 3 to 6 months | Hypertension, target organ damage risk | Systolic > 160 mmHg prompts antihypertensive therapy | | Urine protein:creatinine ratio | Every 6 months | Proteinuria, which predicts progression | UPC > 0.4 prompts ACE inhibitor consideration | | Packed cell volume | Every 6 months | Anemia of CKD | PCV < 25% prompts evaluation for erythropoietin therapy | | Owner-reported quality of life | Every visit | Appetite, activity, vomiting, litter box use | Decline prompts palliative care discussion | The monitoring schedule should be individualised. A stable IRIS stage 2 cat with normal blood pressure and phosphorus may be rechecked every 6 months, while an IRIS stage 4 cat with hypertension and anemia may require monthly or even more frequent evaluation. The ISFM guidelines emphasize that therapy must be adjusted according to individual needs, and that quality of life should be prioritized when multiple interventions are indicated. Documentation should include a problem list, current medications with doses, blood pressure readings, body weight, and laboratory values. This allows the clinician to detect trends instead of single-point abnormalities. Owners should be asked about appetite, water intake, urination frequency, vomiting episodes, and activity level at every visit, as these are the earliest indicators of decompensation. ## Recognized Complications and Early Detection Several complications arise during long-term management of feline CKD, and each has a defined monitoring strategy. **Progressive azotemia and hyperphosphatemia.** Despite dietary phosphorus restriction, some cats continue to show rising creatinine and phosphate concentrations. The ISFM consensus guidelines recommend rechecking biochemistry at intervals appropriate to IRIS stage, with more frequent assessment in advanced disease. Early detection depends on serial measurement instead of single values. A rising trend across two consecutive samples, particularly when accompanied by declining appetite or body condition, warrants intensification of therapy. **Hypertensive target organ damage.** Hypertension can develop or worsen at any point in the disease course. The ISFM hypertension guidelines emphasize that blood pressure should be measured at every recheck visit in cats with CKD, using a consistent technique with Doppler or oscillometric devices. Ocular examination for retinal hemorrhage, detachment, or tortuous vessels should accompany each blood pressure measurement, as ocular lesions may precede systemic signs. **Proteinuria progression.** The magnitude of proteinuria correlates with interstitial fibrosis and glomerular hypertrophy in feline CKD. Serial urine protein:creatinine ratio (UPC) measurement identifies cats progressing from non-proteinuric to borderline or proteinuric status. The IRIS guidelines recommend UPC assessment at diagnosis and at intervals thereafter, with confirmation of persistent proteinuria before initiating or intensifying antiproteinuric therapy. **Hypokalemia and muscle wasting.** Potassium depletion is common in CKD cats and contributes to weakness, ventroflexion, and reduced appetite. Serum potassium should be measured with each biochemistry panel. Cats receiving fluid therapy or diuretics are at particular risk. Early detection allows oral potassium supplementation before clinical signs become pronounced. **Anemia.** Declining hematocrit reflects reduced erythropoietin production and is associated with severity of interstitial fibrosis. Serial packed cell volume measurement identifies progressive anemia. The ISFM guidelines note that anemia management should be considered when hematocrit falls below approximately 20 to 25 percent, with individual patient assessment. **Dehydration and reduced intake.** Subtle dehydration is often missed on physical examination. Serial body weight measurement, skin turgor assessment, and owner-reported water intake provide complementary information. The ISFM guidelines recommend regular weight monitoring as part of the minimum database for CKD cats. ## Common Management Errors and Corrective Actions Less experienced clinicians frequently make several identifiable errors. **Inadequate blood pressure technique.** Blood pressure readings taken in a noisy consultation room, with an incorrectly sized cuff, or after minimal acclimatisation produce unreliable values. The ISFM hypertension guidelines specify that multiple readings should be taken, the first reading discarded, and the cat allowed to settle before measurement. Corrective action includes standardizing cuff width to approximately 30 to 40 percent of limb circumference and using the same limb and position at each visit. **Delaying phosphate control.** Some clinicians defer phosphorus restriction until hyperphosphatemia is marked. The ISFM guidelines recommend dietary phosphorus restriction from IRIS stage 2 onward, with phosphate binders added when diet alone is insufficient. Early intervention slows progression more effectively than rescue therapy. **Underdosing amlodipine.** The ISFM hypertension guidelines note that amlodipine is effective in the majority of cats but that the required dose varies between individuals. Some cats require doses at the higher end of the licensed range or adjunctive therapy. Failure to recheck blood pressure after initiating treatment is a common error. Blood pressure should be reassessed within 7 to 10 days of any dose change. **Overlooking concurrent disease.** Hyperthyroidism can mask or exacerbate renal dysfunction, and hypertension may be driven by thyroid disease instead of CKD alone. The ISFM guidelines emphasize screening for concurrent conditions in older cats. A cat with apparently stable CKD that deteriorates suddenly should be evaluated for new comorbidities. **Inconsistent subcutaneous fluid administration.** Owners may administer fluids irregularly or at inadequate volumes. The ISFM guidelines discuss subcutaneous fluid therapy as an adjunct for cats with dehydration or reduced intake, but emphasize that the approach must be individualised. Clear written instructions and periodic reassessment of the regimen are necessary. ## Troubleshooting Table | Observation | Likely cause | Discriminating check | |---|---|---| | Rising creatinine despite stable diet | Disease progression or dehydration | Compare body weight, skin turgor, urine specific gravity | | Persistent hypertension on amlodipine | Inadequate dose or poor technique | Recheck blood pressure with standardized protocol, consider dose adjustment | | Worsening proteinuria | Progressive fibrosis or uncontrolled hypertension | Repeat UPC, measure blood pressure, review phosphate control | | Hypokalemia on recheck | Renal potassium loss or inadequate intake | Serum potassium, review diet and supplementation | | Falling hematocrit | Progressive CKD or concurrent disease | PCV, reticulocyte count, biochemistry, thyroid status | | Owner reports lethargy after fluids | Fluid overload or too-rapid administration | Assess hydration status, thoracic auscultation, body weight | ## Limitations of Current Evidence The evidence base for several management decisions in feline CKD remains limited. The ISFM guidelines grade the quality of evidence for many interventions as low or moderate, reflecting the scarcity of large randomised controlled trials in feline nephrology. Dietary phosphorus restriction is supported by clinical experience and pathophysiological reasoning, but prospective trial data are limited. The role of protein restriction remains debated, with some experts prioritizing phosphorus control over protein limitation. The use of mesenchymal stem cell therapy has been investigated in a small randomised placebo-controlled trial, which showed no significant adverse effects but also no significant improvement in measured outcomes. This therapy remains experimental, and the ISFM guidelines do not recommend it as standard care. Blood pressure thresholds for intervention are based on consensus instead of trial data. The ISFM hypertension guidelines acknowledge that the optimal target blood pressure is uncertain and that individual patient factors influence treatment decisions. ## Referral and Escalation Criteria Referral to a specialist or advanced diagnostic laboratory is warranted in specific circumstances. Cats with suspected renomegaly, irregular kidney shape, or suspected neoplasia benefit from abdominal ultrasonography. Persistent proteinuria with UPC above 0.4 despite therapy warrants investigation for glomerular disease. Cats with refractory hypertension despite adequate amlodipine dosing may require specialist assessment for alternative or adjunctive antihypertensive therapy. Specialist consultation is appropriate when a cat fails to respond to standard management, when concurrent disease complicates therapy, or when the owner is considering advanced interventions such as renal transplantation. Laboratory involvement may be needed for specialised testing including symmetric dimethylarginine (SDMA) measurement, urine culture, or histopathology. Regulatory reporting is not typically required for feline CKD management. However, clinicians should be aware that some therapeutic agents, particularly those used off-label, may have reporting obligations under local pharmacovigilance schemes. The AVMA practice resources provide guidance on professional obligations regarding adverse event reporting. Where a product is used outside its licensed indication, the clinician should document the rationale and obtain informed consent from the owner. ## Frequently Asked Questions ### How should I prioritize management steps when the owner has limited financial resources? Focus first on interventions with the strongest evidence for slowing progression: dietary phosphorus restriction and consistent blood pressure control. The [ISFM consensus guidelines on feline CKD management](https://pubmed.ncbi.nlm.nih.gov/26936494/) rank these above all other interventions. If a renal diet is unaffordable, discuss phosphorus-restricted home-prepared options with a veterinary nutritionist, or consider intestinal phosphate binders added to a high-quality maintenance diet. Blood pressure measurement should remain non-negotiable, as undetected hypertension accelerates renal injury. Subcutaneous fluids and antiemetics can be added later if funds allow. Reassess priorities at every recheck, because disease trajectory changes what matters most. ### What do I do when Doppler blood pressure equipment is unavailable? Oscillometric devices are an acceptable alternative, though they tend to underestimate systolic pressure in cats. Use the same device for every measurement on that patient, because serial trends matter more than absolute values. The [ISFM hypertension consensus guidelines](https://pubmed.ncbi.nlm.nih.gov/28245741/) emphasize that a reproducible technique and consistent conditions are more important than the specific device. Always record the cuff size, limb used, cat position, and the cat's demeanour score. If only a Doppler is available but the cat is fractious, consider sedation protocols that minimally affect blood pressure, or defer measurement until the next visit instead of accepting a stressed reading that will mislead therapy decisions. ### How should I document monitoring data for long-term CKD cases? Maintain a dedicated chronic disease record that includes a standardized flow sheet: body weight, body condition score, muscle condition score, systolic blood pressure, IRIS stage, serum creatinine, SDMA if available, phosphorus, potassium, packed cell volume, urine protein to creatinine ratio, and urine specific gravity. Record the date of every diet change, medication adjustment, and fluid therapy modification. Note the owner's subjective report of appetite, thirst, and activity using the same questions at every visit. The [ACVIM consensus statement collection](https://www.acvim.org/Animal-Owners/Animal-Education/Consensus-Statements) provides a framework for standardized monitoring in chronic disease. This documentation supports accurate IRIS re-staging and defends clinical decisions if the case is ever reviewed. ### How do I explain the rationale for repeated blood sampling to a reluctant owner? Frame monitoring as the tool that prevents crisis. Explain that CKD changes over months, and blood work is the only way to see those changes before the cat shows clinical signs. Use the IRIS staging system as a visual map: each recheck tells us whether the cat is stable or moving to a higher stage, and that determines whether we adjust diet, fluids, or blood pressure medication. The [ISFM CKD guidelines](https://pubmed.ncbi.nlm.nih.gov/26936494/) describe how therapy must be adjusted according to individual needs, which requires serial data. Offer a reduced-frequency plan if cost is the barrier, but be explicit about what is being deferred and what clinical signs should prompt an earlier visit. ### Does the management protocol differ for a young cat with suspected congenital CKD? Yes, and the differences matter. Young cats often have a longer expected disease duration, so preserving renal function for years instead of months becomes the priority. Growth and body condition require more frequent weight checks, and protein restriction must be balanced against the demands of growth. The [histomorphometric study of feline CKD](https://pubmed.ncbi.nlm.nih.gov/22773469/) shows that interstitial fibrosis correlates most strongly with dysfunction, and young cats may progress differently than geriatric cats. Screen thoroughly for underlying causes such as polycystic kidney disease, renal dysplasia, or ureteral obstruction, because these may have specific interventions. Blood pressure targets and monitoring frequency otherwise follow the same IRIS-based framework. ### What should I tell a colleague who is considering mesenchymal stem cell therapy for a CKD cat? Advise caution. The only published randomised placebo-controlled trial in cats, reported by [Quimby et al. in the Journal of Feline Medicine and Surgery](https://pubmed.ncbi.nlm.nih.gov/25784460/), enrolled eight cats and found no significant improvement in glomerular filtration rate or other measured outcomes, although the treatment was well tolerated. The evidence base is too small to recommend stem cell therapy as a standard intervention. If a client requests it, explain that it remains experimental, that published data do not currently demonstrate benefit, and that proven therapies such as dietary modification and blood pressure control should not be delayed or replaced. Refer to a specialist center if the owner wishes to pursue it through a clinical trial. ## Related Clinical & Scientific Guides * [Feline Hepatic Lipidosis: Nutritional and Medical Management](/knowledge/veterinary-medicine/clinical-internal-medicine/feline-hepatic-lipidosis-nutritional-medical-management) * [Canine Respiratory Infection: Diagnostic Approach and Treatment](/knowledge/veterinary-medicine/clinical-internal-medicine/canine-respiratory-infection-diagnostic-approach-treatment) * [Canine Respiratory Virus: Diagnostic and Management Considerations](/knowledge/veterinary-medicine/clinical-internal-medicine/canine-respiratory-virus-diagnostic-management-considerations) ## References and Further Reading - [ISFM Consensus Guidelines on the Diagnosis and Management of Hypertension in Cats.](https://pubmed.ncbi.nlm.nih.gov/28245741/). 2017. - [ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease.](https://pubmed.ncbi.nlm.nih.gov/26936494/). 2016. - [Assessment of intravenous adipose-derived allogeneic mesenchymal stem cells for the treatment of feline chronic kidney disease: a randomized, placebo-controlled clinical trial in eight cats.](https://pubmed.ncbi.nlm.nih.gov/25784460/). 2016. - [Comparison of two host cell range variants of feline immunodeficiency virus.](https://pubmed.ncbi.nlm.nih.gov/1697907/). 1990. - [Chronic Kidney Disease in Aged Cats: Clinical Features, Morphology, and Proposed Pathogeneses.](https://pubmed.ncbi.nlm.nih.gov/26869151/). 2016. - [Histomorphometry of feline chronic kidney disease and correlation with markers of renal dysfunction.](https://pubmed.ncbi.nlm.nih.gov/22773469/). 2013. - [ACVIM Consensus Statements](https://www.acvim.org/Animal-Owners/Animal-Education/Consensus-Statements). Journal of Veterinary Internal Medicine. - [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual. - [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association. ## Related Articles - [Feline Chronic Enteropathy: Diagnostic and Management Framework](/knowledge/veterinary-medicine/clinical-internal-medicine/feline-chronic-enteropathy-diagnostic-management-framework) - [Feline Immune-Mediated Disease: Diagnostic Approach and Management](/knowledge/veterinary-medicine/clinical-internal-medicine/feline-immune-mediated-disease-diagnostic-approach-management) - [Canine Chronic Kidney Disease: Staging and Therapeutic Plan](/knowledge/veterinary-medicine/clinical-internal-medicine/canine-chronic-kidney-disease-staging-therapeutic-plan) - [Feline Systemic Hypertension: Screening and Management](/knowledge/veterinary-medicine/clinical-internal-medicine/feline-systemic-hypertension-screening-management) - [Feline Hypertrophic Cardiomyopathy: Screening and Management](/knowledge/veterinary-medicine/clinical-internal-medicine/feline-hypertrophic-cardiomyopathy-screening-management) > This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.